Monique Oye, DO
Internal Medicine · Charlotte, NCNPI 1689179194
Payments from drug & device makers
Across 55 payments — averaging $77.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$2K
- Abiomed$838
- Edwards Lifesciences$212
- Biosense Webster, Inc.$171
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$131
- Boston Scientific$122
- plus $444 from 8 others
What the payments were for
- Travel & lodging$1,82043%
- Food & beverage$2,04748%
- Education$41310%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 21 | $2,361 |
| Abiomed | 5 | $838 |
| Edwards Lifesciences | 3 | $212 |
| Biosense Webster, Inc. | 4 | $171 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 9 | $131 |
| Boston Scientific | 2 | $122 |
| Bard Peripheral Vascular, Inc. | 1 | $104 |
| Cardiovascular Systems Inc. | 1 | $96 |
| Angiodynamics, Inc. | 2 | $81 |
| Novartis | 2 | $50 |
| Johnson & Johnson | 1 | $40 |
| Chiesi USA, Inc. | 2 | $33 |
| Terumo Medical Corporation | 1 | $22 |
| Lantheus Medical Imaging, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GALLANT$1,248
- Impella$787
- EnSite Precision Cardiac Mapping System$208
- ENSITE$205
- PASCAL$134
- WATCHMAN Access System$105
- NA$103
How this compares
$4,280 in reported general payments places this provider in the 85th percentile of 3,302 internal medicine providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 15 | $15,489 |
| Rosuvastatin Calcium | 14 | $297 |
| Atorvastatin Calcium | 17 | $245 |
| Carvedilol | 23 | $218 |
| Amlodipine Besylate | 11 | $62 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Charlotte
- Saad UsmaniCharlotte$16.2M
- Christina KennellyCharlotte$15.4M
- Lyndsay MolinariCharlotte$2.4M
- Claud GriggCharlotte$1.5M
- Maher AghaCharlotte$1M
- Jonathan SchwartzCharlotte$824K
- Marc JohnsonCharlotte$823K
- Santosh GopalakrishnanCharlotte$598K
- Maithili ChitnavisCharlotte$536K
- Christopher FerreriCharlotte$434K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.